Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
Holding MNPR?
Track your performance easily

Monopar Therapeutics Inc (MNPR) Income Statement

354 Followers

Monopar Therapeutics Inc Income Statement

Last quarter (Q2 2024), Monopar Therapeutics Inc's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Monopar Therapeutics Inc's net income was $-1.72M. See Monopar Therapeutics Inc’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 4.46M$ 8.83M$ 10.54M$ 9.13M$ 6.51M$ 4.32M
Operating Income
$ -7.91M$ -8.83M$ -10.54M$ -9.13M$ -6.51M$ -4.32M
Net Non Operating Interest Income Expense
$ 396.12K$ 429.04K$ 21.24K$ 24.02K$ 81.90K$ 98.89K
Other Income Expense
--$ -15.04K-$ 122.40K-
Pretax Income
$ -4.06M$ -8.40M$ -10.50M$ -9.10M$ -6.30M$ -4.22M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -7.51M$ -8.40M$ -10.50M$ -9.10M$ -6.30M$ -4.22M
Basic EPS
$ -0.50$ -0.61--$ -0.58$ -0.45
Diluted EPS
$ -0.50$ -0.61-$ -0.73$ -0.58$ -0.45
Basic Average Shares
$ 61.03M$ 13.82M$ 12.72M$ 12.47M$ 10.96M$ 9.32M
Diluted Average Shares
$ 61.03M$ 13.82M$ 12.72M$ 12.47M$ 10.96M$ 9.32M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 4.46M$ 8.83M$ 10.54M$ 9.13M$ 6.51M$ 4.32M
Net Income From Continuing And Discontinued Operation
$ -7.51M$ -8.40M$ -10.52M$ -9.10M$ -6.30M$ -4.22M
Normalized Income
$ -4.98M-$ -8.30M-$ -6.43M$ -4.22M
Interest Expense
------
EBIT
$ -4.46M$ -8.83M$ -10.52M$ -9.13M$ -6.51M$ -4.32M
EBITDA
$ -4.46M$ -8.83M$ -10.52M$ -9.13M$ -6.51M$ -4.32M
Currency in USD

Monopar Therapeutics Inc Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis